Skip to main content
SpringerLink
Log in

Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen

  • Chapter
  • First Online:
Therapieresistenz bei Depressionen und bipolaren Störungen

  • 1689 Accesses

Zusammenfassung

Eine Therapieresistenz auf verschiedene pharmakologische und psychotherapeutische Behandlungsoptionen betrifft je nach Studienlage bis zu einem Drittel aller PatientInnen mit einer unipolaren Depression (Fava 2003; Whiteford et al. 2013). Dabei wurden wiederholt therapeutische Optionen jenseits der Behandlung mit Antidepressiva untersucht. In den letzten Jahren gab es zunehmende Evidenz für die Wirksamkeit weiterer Substanzgruppen wie z. B. die atypischen Antipsychotika. Im folgenden Kapitel werden verschiedene Stoffklassen und deren Wirksamkeit in der Behandlung der unipolaren Depression, insbesondere unter Betrachtung der Therapieresistenz besprochen. Ein Schwerpunkt liegt hierbei auf der wissenschaftlichen Evidenz für deren Wirksamkeit bzw. Nichtwirksamkeit sowie auf praktischen Behandlungsempfehlungen für die einzelnen Substanzen. Zusätzlich soll aber auch eine kritische Abwägung hinsichtlich des Risiko-Nutzen-Verhältnisses, insbesondere in Bezug auf potenzielle Nebenwirkungen erfolgen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101. https://doi.org/10.1016/S0893-133X(97)00112-7

    Article  CAS  PubMed  Google Scholar 

  • Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–385. https://doi.org/10.3109/15622975.2013.804195

  • Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540–549. https://doi.org/10.4088/jcp.08m04629

    Article  CAS  PubMed  Google Scholar 

  • Benasi G, Guidi J, Offidani E, Balon R, Rickels K, Fava GA (2018) Benzodiazepines as a monotherapy in depressive disorders: a systematic review. Psychother Psychosom 87:65–74. https://doi.org/10.1159/000486696

    Article  PubMed  Google Scholar 

  • Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197–206. https://doi.org/10.1017/s1092852900020216

    Article  PubMed  Google Scholar 

  • Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843–853. https://doi.org/10.4088/jcp.v68n0604

    Article  CAS  PubMed  Google Scholar 

  • Bond DJ, Lam RW, Yatham LN (2010) Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 124:228–234. S0165-0327(09)00501-1[pii] 10.1016/j.jad.2009.11.008

    Google Scholar 

  • Bushnell GA, Sturmer T, Gaynes BN, Pate V, Miller M (2017) Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001–2014. JAMA Psychiat 74:747–755. https://doi.org/10.1001/jamapsychiatry.2017.1273

    Article  Google Scholar 

  • Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88

    Article  CAS  PubMed  Google Scholar 

  • Cantu F, Ciappolino V, Enrico P, Moltrasio C, Delvecchio G, Brambilla P (2021) Augmentation with atypical antipsychotics for treatment-resistant depression. J Affect Disord 280:45–53. https://doi.org/10.1016/j.jad.2020.11.006

    Article  CAS  PubMed  Google Scholar 

  • Chang CM, Sato S, Han C (2013) Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 27 Suppl 1:S21-7. https://doi.org/10.1007/s40263-012-0030-1

  • Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372. https://doi.org/10.1002/da.20130

    Article  CAS  PubMed  Google Scholar 

  • Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K (1991) Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 52:472–476

    CAS  PubMed  Google Scholar 

  • Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, and Wiles N (2019) Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 12:CD010557. https://doi.org/10.1002/14651858.CD010557.pub2

  • Davis LL, Bartolucci A, Petty F (2005) Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 85:259–266. S0165-0327(04)00371-4[pii] 10.1016/j.jad.2004.09.009

    Google Scholar 

  • Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F (1996) Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 32:647-52.

    Google Scholar 

  • DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR, Modafinil in Depression Study G (2003) Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 64:1057–1064. https://doi.org/10.4088/jcp.v64n0911

  • DGPPN B, and KBV A. 2015. „für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale Versor-gungs Leitlinie Unipolare Depression–Langfassung, 2. Auflage. Version 5. 2015.“ In

    Google Scholar 

  • Dold M, Bartova L, Fugger G, Mitschek MMM, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S (2020) Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. Eur Neuropsychopharmacol 41:70–80. https://doi.org/10.1016/j.euroneuro.2020.09.636

    Article  CAS  PubMed  Google Scholar 

  • Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT (2007) Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 27:614–619. https://doi.org/10.1097/jcp.0b013e31815abefb

    Article  CAS  PubMed  Google Scholar 

  • Earley WR, Guo H, Nemeth G, Harsanyi J, Thase ME (2018) Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 48:62–80

    PubMed  PubMed Central  Google Scholar 

  • Edwards KR, Sackellares JC, Vuong A, Hammer AE, Barrett PS (2001) Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double-Blind Comparison with Valproate. Epilepsy Behav 2:28–36. https://doi.org/10.1006/ebeh.2000.0143

    Article  PubMed  Google Scholar 

  • El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13:917-32. doi:https://doi.org/10.1017/S1461145710000015

  • Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659. https://doi.org/10.1016/s0006-3223(03)00231-2

    Article  PubMed  Google Scholar 

  • Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59:1052–1060. https://doi.org/10.1016/j.biopsych.2006.01.016

    Article  CAS  PubMed  Google Scholar 

  • Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81:87–97. https://doi.org/10.1159/000332050

    Article  PubMed  Google Scholar 

  • Fava M, Thase ME, DeBattista C (2005) A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 66:85–93. https://doi.org/10.4088/jcp.v66n0112

    Article  CAS  PubMed  Google Scholar 

  • Furukawa TA, Streiner DL, and Young LT (2002) Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev:CD001026. doi:https://doi.org/10.1002/14651858.CD001026

  • Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9. 194/1/4[pii] https://doi.org/10.1192/bjp.bp.107.048504

  • Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT (2007) Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 68:1840–1844

    Article  CAS  PubMed  Google Scholar 

  • Goh KK, Chen CH, Chiu YH, Lu ML (2019) Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. J Psychopharmacol 33:700–713. https://doi.org/10.1177/0269881119844199

    Article  CAS  PubMed  Google Scholar 

  • Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74:1101–1107. https://doi.org/10.4088/JCP.13r08560

    Article  CAS  PubMed  Google Scholar 

  • Health NCCfM (2010) „Depression: the treatment and management of depression in adults (updated edition).“ In.: British Psychological Society.

    Google Scholar 

  • Jon DI, Kim DH, Seo HJ, Kwon YJ, Kim MD, Yang JC, Suh HS, Min KJ, Pae CU, Bahk WM (2013) Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Clin Neuropharmacol 36:157–161. DOI: 10.1097/WNF.0b013e3182a31f3d

    Article  CAS  PubMed  Google Scholar 

  • Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43:205–214. https://doi.org/10.1016/j.jpsychires.2008.05.003

    Article  PubMed  Google Scholar 

  • Kishi T, Matsunaga S, Iwata N (2017) Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 267:149–161. https://doi.org/10.1007/s00406-016-0706-5

    Article  PubMed  Google Scholar 

  • Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Kohler S (2017) Efficacy of off-label augmentation in unipolar depression: a systematic review of the evidence. Eur Neuropsychopharmacol 27:423–441. https://doi.org/10.1016/j.euroneuro.2017.03.003

    Article  CAS  PubMed  Google Scholar 

  • Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd (2006) Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 14:181–185. https://doi.org/10.1097/01.JGP.0000192503.10692.9f

    Article  PubMed  Google Scholar 

  • Li X, Xing B, Yu E, Chen W, Wu H (2013) The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci 25:157–160. https://doi.org/10.1176/appi.neuropsych.12070171

    Article  PubMed  Google Scholar 

  • Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, and Goodwin G (2003) Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev:CD004052. https://doi.org/10.1002/14651858.CD004052

  • Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, and Gharabawi-Garibaldi GM (2007) Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147:593–602. https://doi.org/10.7326/0003-4819-147-9-200711060-00003

  • Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156–165. https://doi.org/10.1097/JCP.0b013e31816774f9

    Article  CAS  PubMed  Google Scholar 

  • Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991. https://doi.org/10.1176/appi.ajp.2009.09030312

    Article  PubMed  Google Scholar 

  • Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa TA (2019) Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 6:CD001026. https://doi.org/10.1002/14651858.CD001026.pub2

  • Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K (1996) Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol 11:55–57. https://doi.org/10.1097/00004850-199603000-00008

    Article  CAS  PubMed  Google Scholar 

  • Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P (2006) A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 26:653–656. https://doi.org/10.1097/01.jcp.0000246212.03530.fd

    Article  CAS  PubMed  Google Scholar 

  • Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986) Antidepressant effects of carbamazepine. Am J Psychiatry 143:29–34. https://doi.org/10.1176/ajp.143.1.29

    Article  CAS  PubMed  Google Scholar 

  • Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB (2006) Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505–2513. https://doi.org/10.1038/sj.npp.1301113

    Article  CAS  PubMed  Google Scholar 

  • Ravindran AV, Kennedy SH, O’Donovan MC, Fallu A, Camacho F, Binder CE (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69:87–94. https://doi.org/10.4088/jcp.v69n0112

    Article  CAS  PubMed  Google Scholar 

  • Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29–39. https://doi.org/10.1016/s0024-3205(00)00911-5

    Article  CAS  PubMed  Google Scholar 

  • Rybakowski JK, Suwalska A, and Chlopocka-Wozniak M (1999) Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40:134-9. https://doi.org/10.1159/000026610

  • Schifano F, Chiappini S, Corkery JM, Guirguis A (2019) An insight into z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol 22:270–277. https://doi.org/10.1093/ijnp/pyz007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411. https://doi.org/10.1038/sj.npp.1300203

    Article  CAS  PubMed  Google Scholar 

  • Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131–134. https://doi.org/10.1176/appi.ajp.158.1.131

    Article  CAS  PubMed  Google Scholar 

  • Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL (2010) Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 122:1–9. S0165-0327(09)00495-9[pii] 10.1016/j.jad.2009.10.033

    Google Scholar 

  • Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10:e1001403. https://doi.org/10.1371/journal.pmed.1001403

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Svestka J, Rysanek R, Ceskova E (1991) Treatment of endogenous depressions with valpromide (open study). Homeost Health Dis 33:291–292

    CAS  PubMed  Google Scholar 

  • Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 76:1232–1240. https://doi.org/10.4088/JCP.14m09689

    Article  PubMed  Google Scholar 

  • Vazquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ (2021) Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol 35:890–900. https://doi.org/10.1177/02698811211013579

    Article  CAS  PubMed  Google Scholar 

  • Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382:1575–1586. https://doi.org/10.1016/S0140-6736(13)61611-6

  • Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, Wang HH, Ma XC, Chen C, Wang W, Guo L, Zhang YH, Yang XB, Yang GD (2007) Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 41:360–369. S0022-3956(05)00079-8[pii] https://doi.org/10.1016/j.jpsychires.2005.06.002

  • Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76:e487–e498. https://doi.org/10.4088/JCP.14r09204

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, CCM, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Stephan Köhler & Cora Schefft

Authors
  1. Stephan Köhler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cora Schefft
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Köhler .

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland

    Michael Bauer

  2. Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité – Universitätsmedizin Berlin, Berlin, Deutschland

    Anne Berghöfer

  3. Klinische Psychologie und Psychotherapie, Zentrum für Psychologische Psychotherapie, Universität Greifswald, Greifswald, Deutschland

    Eva-Lotta Brakemeier

  4. Fliedner Klinik Berlin und Klinik für Psychiatrie und Psychotherapie, Campus Mitte, Charité - Universitätsmedizin Berlin, Berlin, Deutschland

    Mazda Adli

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Köhler, S., Schefft, C. (2022). Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen. In: Bauer, M., Berghöfer, A., Brakemeier, EL., Adli, M. (eds) Therapieresistenz bei Depressionen und bipolaren Störungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-65734-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-65734-8_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-65733-1

  • Online ISBN: 978-3-662-65734-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation